Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
VolitionRx Limited's new finger-prick test shows utility in diagnosing sepsis patients at the point of care, removing the need for centralized labs and targeting the $3.8 billion global NETosis testing market.
VolitionRx Limited has demonstrated the effectiveness of its rapid, point-of-care finger-prick blood test for identifying sepsis patients. This development aims to eliminate the dependency on centralized laboratory analysis, allowing for quicker diagnosis directly where patients are being treated.
The technology focuses on NETosis testing, a diagnostic area with an estimated global addressable market of $3.8 billion. Sepsis is a life-threatening condition where rapid and accurate diagnosis is critical for patient survival and effective treatment.
Volition's epigenetics-based approach analyzes blood samples obtained via a simple finger prick. This method simplifies the diagnostic process and potentially reduces turnaround times compared to traditional laboratory methods.
The company is advancing the development and potential commercialization of this test. Further details on the clinical results are expected to be released.